Long-term follow-up in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention

Viktor Klancík1,2,3*, Ladislav Pesl3, Marek Neuberg4, Petr Tousek1,2, and Viktor Kocka1,2

1Third Faculty of Medicine, Charles University, Prague, Ruska 2411, 100 00, Czech Republic
2Department of Cardiology, University Hospital Kralovske Vinohrady, Prague, Srobarova 50, 100 00, Czech Republic
3Department of Cardiology, Hospital Ceske Budejovice, a.s., Ceske Budejovice, B. Nemcove 585/54, 370 01, Czech Republic
4Medtronic Czechia, Partner of INTERCARDIS Project, Prague, Prosecka 852/66, 190 00, Czech Republic

KEYWORDS
Long term; Follow-up; STEMI; pPCI

Long-term follow-up after primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) beyond 5 years is poorly described. There are no risk-stratification systems available for routine use. This retrospective, academic, two-centre analysis included consecutive patients who presented with acute STEMI between March 2008 and December 2019. In total, 5263 patients underwent pPCI; all patients were included in the analysis only once. Baseline characteristics were gathered from prospective local registries and based on initial hospitalization. The study enrolled 5263 patients who had been treated with pPCI; it found that cardiovascular mortality was the most frequent cause of death (65.0%) on long-term follow-up to 12 years. Myocardial infarction associated mortality was 27.2%. Cardiovascular mortality was dominant, including in the landmark analysis beyond 1 year. Multivariate analysis identified significant predictors for long-term cardiovascular mortality: age, history of diabetes mellitus, history of renal insufficiency, history of heart failure, Killip class, and successful pPCI at presentation. A predictive model was built to evaluate the risk of cardiovascular death with a high discrimination value (C-statistic = 0.84). Cardiovascular diseases remain the leading cause of long-term mortality after pPCI in the Central European population. Our novel predictive model provides risk stratification; it could identify patients who would experience the greatest benefit from aggressive secondary prevention measures.

Introduction

Primary percutaneous coronary intervention (pPCI) is a well-established minimally invasive non-surgical treatment for ST-segment elevation myocardial infarction (STEMI). To our knowledge, there have been few long-term follow-up reports beyond 5 years for STEMI patients who underwent pPCI. Previous studies have reported long-term 5-year or longer follow-ups and mortality rates after STEMI.1–9 Despite the use of pPCI, overall long-term mortality after STEMI remains high: ~20.0% over 5 years.10 The annual risk of mortality between 1 and 5 years after STEMI was ~2.0% per year.5,9,10 Cardiovascular mortality over 5 years of follow-up has been reported to range from 4.7% to 16.0%.1,2,4,5,8,9 Annual cardiac mortality in STEMI patients has been reported to range from 1.1% to 1.5%.4,5,10
Swedish trial [3] reported the complete dataset of all STEMI patients who underwent pPCI between 2006 and 2010 from the national SWEDHEART registry. A study of cardiovascular mortality after pPCI for STEMI [5] demonstrated that cardiovascular problems were the leading cause of death in the first 6 months.

A predictive model for the cardiovascular mortality risk over long-term follow-up may help to identify patients who could benefit from intensive secondary preventive care. The aim of this study was to analyse missing information concerning long-term outcomes in STEMI patients treated with pPCI in the Czech Republic.

Methods

This retrospective, two-centre analysis included all consecutive patients who presented with acute STEMI between March 2008 and December 2019. The study was approved by the Ethics Committee of the Third Faculty of Medicine, Charles University. The study was performed in accordance with the Declaration of Helsinki. All patients were treated with pPCI and included in the study only once. Baseline characteristics were gathered from prospective local registries and based on initial-hospitalization data. Cardiovascular risk factors and comorbidities were evaluated using medical histories obtained at the time of initial presentation. Mortality data were extracted from the State Institute of Health Information and Statistics of the Czech Republic on 14 May 2021. The complete dataset contained information regarding the date of death and primary cause of death on the basis of the International Classification of Diseases-10 (ICD-10). Cardiovascular mortality was defined as ICD-10 cardiac categories I2xx, I4xx, I5xx, and I6xx. Tumour-associated mortality was defined as ICD-10 tumour categories C and D. Standard definitions of comorbidities, time intervals, and interpretations of coronary angiography were used. Successful pPCI was defined as final residual stenosis <20% of the diameter and thrombolysis in myocardial infarction flow 3 by the operator.

The ejection fraction of the left ventricle was evaluated based on echocardiography performed prior to discharge. The Killip class of heart failure was determined at admission in the catheterization laboratory (CathLab). Symptoms-to-CathLab was defined as the interval between patient symptom onset and patient arrival in the CathLab. The STEMI localization was evaluated on the basis of the type of myocardial infarction during discharge; only anterior and inferior myocardial infarctions were included because of clear identification on electrocardiography. Coronary angiography was used to assess the number of diseased coronary arteries, regardless of the causative lesion. Landmark analysis was performed beyond 1 year to exclude cardiovascular mortality related to the myocardial infarction at presentation.

Statistical analysis

The Kolmogorov-Smirnov test for goodness-of-fit was used to determine the normality of the data distribution. Continuous variables are presented as means and standard deviations. Continuous variables were analysed using Student’s t-test or the Mann-Whitney U-test. Categorical variables were analysed using the χ² test and Fisher’s exact test. Kaplan-Meier survival analysis was used to calculate the cumulative survival at different time intervals; the log-rank test was used to assess differences in survival. Landmark analysis was used to evaluate the impacts of predictors on mortality. Logistic regression was performed to evaluate the effects of selected predictors on cardiovascular mortality. Predictors of mortality in the univariate analysis with P-values <0.05 were entered into a backwards stepwise logistic regression model. The predictors that remained significant with P-values <0.05 were retained in the final model. A receiver operator characteristic curve was used for the analysis of the risk scores to assess discrimination; the Hosmer-Lemeshow goodness-of-fit test was used to assess calibration. Results were considered statistically significant at P-values <0.05. All statistical analyses were performed using SPSS Statistics software, version 26 (IBM Corp., Armonk, NY, USA).

Graphical analyses were performed using Sigma Plot, version 14.

Results

In total, 5263 STEMI patients were treated with pPCI in two centres between March 2008 and December 2019; the mean follow-up duration was 5.1 years. The mean patient age was 63.9 years; of the patients, 29.3% were women and 70.7% were men. The majority of the patients exhibited Killip Class 1 heart failure at the time of admission. The inferior/posterior STEMs were slightly more common than anterior STEMs. Approximately half of the patients had single-vessel disease; two-thirds of the patients had a good left ventricular ejection fraction (LVEF) on discharge.

The baseline characteristics of the sample are shown in Table 1.

Mortality data

Overall mortality was 26.5% during 12 years of follow-up after pPCI. Approximately two-thirds of the patients (65%) died of cardiovascular causes, while one-third of the patients (35%) died of non-cardiovascular causes. Myocardial infarction-associated mortality was 27.2%. Cardiovascular mortality after STEMI was the main cause of death in the 1st year of follow-up. Kaplan-Meier analysis demonstrated consistently higher risk of cardiovascular mortality after pPCI, compared with tumour-related mortality and other causes of mortality.

The long-term cardiovascular mortality data are shown in Figure 1.

Cardiovascular mortality

Univariate predictors for long-term cardiovascular mortality

Univariate analysis revealed factors with a significant influence on cardiovascular mortality: age, sex, arterial hypertension, stroke, renal insufficiency, diabetes mellitus,
myocardial infarction, heart failure, active smoking, Killip score, STEMI localization, single- or multi-vessel disease, successful pPCI, and LVEF. Patients who were smokers at the time of presentation demonstrated significantly better cardiovascular outcomes. Histories of stroke and renal insufficiency were the strongest predictors for cardiovascular outcomes, with an incidence approximately two-fold higher than in other patients. Patients with cardiovascular mortality were significantly older (73.7 years) at presentation, compared with the remaining patients (61.9 years). Cardiovascular mortality was higher in women (24.3%) than in men (14.3%) ($P < 0.0001$). Women (77.2 ± 11.2 years) were significantly older ($P < 0.0001$) than men (71.2 ± 11.6 years). No significant differences were found in the symptom-to-CathLab time among survivors and deceased individuals ($P = 0.102$). Most cardiovascular deaths were caused by myocardial ischaemia and heart failures, while pulmonary embolisms and strokes were reported as the causes of death in 9 and 53 patients, respectively.

The predictors for adverse outcomes in STEMI patients after pPCI are shown in Table 2.

### Discussion

Long-term mortality after STEMI remains high. The result of this trial is unique about the possibility of identifying patients with a high risk of cardiovascular death with little or no symptoms.

Cardiovascular diseases were responsible for most deaths in our cohort, including in the landmark analysis after the 1st year.

We built a predictive model based on the multivariate predictor analysis. This predictive model could identify patients at high risk of cardiovascular death in the long-term perspective.

Geographical differences may influence cardiovascular mortality. A Scandinavian study [4] found that non-cardiovascular mortality was the major cause of death during long-term follow-up beyond 30 days after pPCI for STEMI; in our study, cardiovascular mortality was the major cause of death. These findings could reflect different lifestyles among nations. In the Czech Republic, there is a high prevalence of cardiovascular risk factors. [1] These geographical differences may have impacts on local primary and secondary preventive care.

In a previous study [3], multivariate analysis showed that independent risk factors for all-cause mortality on follow-up beyond 6 months after pPCI for STEMI included advanced age, previous heart failure, renal dysfunction, and liver cirrhosis. In our study, multivariate analysis showed that predictors for cardiovascular mortality were similar to

### Table 1 Baseline characteristics of the study population

| Baseline characteristics                      |
|----------------------------------------------|
| Age (years, mean ± standard deviation)       |
| 63.9 ± 12.8                                  |
| Sex (female/male)                            |
| 29.3%/70.7                                   |
| Medical history at presentation              |
| Known arterial hypertension                   |
| 53.4%                                        |
| Previous stroke                              |
| 4.8%                                         |
| Known renal insufficiency                     |
| 2.5%                                         |
| Known diabetes mellitus                       |
| 22.0%                                        |
| Previous myocardial infarction                |
| 14.8%                                        |
| Previous heart failure                        |
| 1.9%                                         |
| Active smokers                                |
| 56.7%                                        |
| Clinical characteristics at presentation     |
| Pain to CathLab (min, mean ± standard deviation) |
| 263.3 ± 266.6                                 |
| Killip class                                  |
| Class 1                                      |
| 84.0%                                        |
| Class 2                                      |
| 7.0%                                         |
| Class 3                                      |
| 1.8%                                         |
| Class 4                                      |
| 5.8%                                         |
| STEMI localization                            |
| Anterior STEMI                                |
| 41.9%                                        |
| Inferior/posterior STEMI                      |
| 47.6%                                        |
| Other                                        |
| 10.5%                                        |
| Coronary angiography                          |
| One-vessel disease                            |
| 48.5%                                        |
| Two-vessel disease                            |
| 29.0%                                        |
| Three-vessel disease                          |
| 21.5%                                        |
| Successful pPCI                               |
| 95.9%                                        |
| Clinical characteristics during discharge     |
| LVEF %                                       |
| LVEF >50%                                    |
| 62.5%                                        |
| LVEF 30-49%                                   |
| 33.5%                                        |
| LVEF <30%                                     |
| 4.0%                                         |

CathLab, catheterization laboratory; LVEF, left ventricle ejection fraction; pPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

### Multivariate predictors for long-term cardiovascular mortality and predictive model

Multivariate analysis revealed independent predictors for cardiovascular mortality (Table 3). Significant predictors based on the regression analysis were identified in the following categories: age, diabetes mellitus, renal insufficiency, heart failure, Killip class, and successful/unsuccessful pPCI. A predictive model was built to evaluate the risk of cardiovascular death with a high discrimination value (C-statistic = 0.84). The receiver operating characteristic curve for the predictive model is shown in Figure 2.

The equation to assess the long-term risk of cardiovascular death is:

\[
\text{logit} p = -8.737 + (0.330 \times \text{known diabetes mellitus}) \\
+ (0.731 \times \text{Killip class}) \\
+ (0.722 \times \text{known renal insufficiency}) \\
+ (1.246 \times \text{past heart failure}) \\
+ (0.015 \times \text{successful/unsuccessful pPCI}) \\
+ (0.091 \times \text{age})
\]

### Landmark analysis

Cardiovascular mortality was assessed for 1 year and up to 12 years. Landmark analysis was performed beyond 1 year to exclude cardiovascular mortality related to myocardial infarction at presentation. The presence of renal insufficiency was the predictor with the worst outcome. Landmark analysis demonstrated the following predictors: diabetes mellitus, renal insufficiency, Killip class, and successful/unsuccessful pPCI (Figure 3).

---

**Table 2**

| Baseline characteristics | STEMI patients | Control patients |
|--------------------------|----------------|-----------------|
| Age (years)              | 61.9 ± 11.9    | 59.3 ± 11.5     |
| Sex (female/male)        | 70.7%/29.3%    | 71.2%/28.8%     |
| BMI (kg/m²)              | 26.3 ± 4.8     | 25.9 ± 4.7      |
| Smoking status           | 56.7%          | 49.3%           |
| Hypertension             | 53.4%          | 46.2%           |
| Diabetes mellitus        | 22.0%          | 18.9%           |
| Renal insufficiency      | 2.5%           | 1.9%            |
| Heart failure            | 1.9%           | 1.7%            |
| Killip class             |                |                 |
| Class 1                  | 84.0%          | 82.1%           |
| Class 2                  | 7.0%           | 7.5%            |
| Class 3                  | 1.8%           | 1.5%            |
| Extension of STEMI       |                |                 |
| Anterior STEMI           | 41.9%          | 43.2%           |
| Inferior/posterior STEMI | 47.6%          | 49.5%           |
| Other                    | 10.5%          | 6.3%            |
| ST-segment elevation     |                |                 |
| Myocardial infarction    |                |                 |
| Anterior STEMI           | 47.6%          | 49.3%           |
| Inferior/posterior STEMI | 41.9%          | 48.5%           |
| Other                    | 10.5%          | 12.5%           |
| Successful pPCI          | 95.9%          | 95.6%           |

CathLab, catheterization laboratory; LVEF, left ventricle ejection fraction; pPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
the predictors for all-cause mortality; they included age, renal insufficiency, and previous heart failure (Table 3). Predictors for 1-year cardiac mortality were identified in a previous study: age, diabetes mellitus, Killip class, cardiac arrest, creatinine, haemoglobin and troponin on admission, and left ventricular ejection fraction during hospitalization. Predictors for long-term cardiovascular mortality after the 1st year were age, diabetes mellitus, renal insufficiency, previous heart failure, Killip class at presentation, and successful pPCI. Patients who were smokers at presentation had better outcomes than did non-smokers. This paradox was previously reported; it presumably arises because many patients quit smoking for secondary prevention.

With respect to the predictive model for cardiovascular mortality presented above, patient stratification could help to provide more focused secondary preventive care for high-risk patients. Modern hypolipidaemic treatment using PCSK9 inhibitors is effective for high-risk patients. For better follow-up, computed tomography angiography, stress examinations, and other examinations may be used.

The Pain-to-CathLab time was not a significant predictor for long-term cardiovascular mortality. In the event of chest pain, early emergency calls could shorten the time from pain to diagnosis. However, the quality of the time period reported by the patients and physicians is also questionable. Mortality in women was higher because women in the sample were significantly older (6.0 years).

Recurrent angina is a significant symptom in long-term follow-up in patients after pPCI for STEMI which may have an important impact on the intensity of the follow-up. Patients with recurrent stable angina are more likely to be older, women with previous heart failure, multi-vessel disease and have a higher risk of coronary revascularization in long-term follow-up against patients without stable angina. The presence of stable angina is weakly associated with cardiovascular mortality, myocardial infarction, and stroke.

In the Czech Republic, patients have regular check-ups via ambulatory cardiologists in secondary prevention of cardiovascular morbidity and mortality. Patients with recurrent angina are often seen by an ambulatory cardiologist before an acute coronary syndrome occurs. The question is how to identify patients with little or no symptoms.

The matter of more intensive long-term follow-up in patients after STEMI with the presence of severe comorbidities identified via our trial is debatable. On the one hand, the specific and more expensive treatment is usually reserved for patients with better prognoses, mostly patients with less comorbidities. But on the other hand, more intensive follow-up may have an impact not only on the higher usage of expensive medication but also may focus better on compensation of blood pressure, diabetes mellitus, etc. via standard medication resulting in better compensation of comorbidities. These factors may have an impact on long-term cardiovascular outcomes. Better compensation...
Table 2  Cardiovascular mortality

| Cardiovascular death                      | No (n = 4352) | Yes (n = 911) | P-value |
|-------------------------------------------|---------------|---------------|---------|
| Baseline characteristics                 |               |               |         |
| Age (years, mean ± standard deviation)   | 61.9 ± 12.0   | 73.7 ± 11.7   | <0.001  |
| Sex (female/male)                         | 75.7%/85.7%   | 24.3%/14.3%   | <0.001  |
| Medical history at presentation           |               |               |         |
| Known arterial hypertension               | 14.0%         | 20.1%         | <0.001  |
| Previous stroke                           | 22.2%         | 51.7%         | <0.001  |
| Known renal insufficiency                 | 22.7%         | 56.3%         | <0.001  |
| Known diabetes mellitus                   | 15.3%         | 24.3%         | <0.001  |
| Previous myocardial infarction            | 21.6%         | 35.1%         | <0.001  |
| Previous heart failure                    | 9.9%          | 18.5%         | <0.001  |
| Active smokers                            | 15.9%         | 8.1%          | <0.001  |
| Clinical characteristics at presentation  |               |               |         |
| Pain to CathLab (min, mean ± standard deviation) | 261.6 ± 269.6 | 269.0 ± 256.4 | 0.102   |
| Killip class                              |               |               |         |
| Class 1                                   | 87.6%         | 12.4%         |         |
| Class 2                                   | 64.6%         | 35.4%         |         |
| Class 3                                   | 55.7%         | 44.3%         |         |
| Class 4                                   | 43.2%         | 56.8%         |         |
| STEMI localization                        |               |               |         |
| Anterior STEMI                            | 81.2%         | 18.8%         | 0.001   |
| Inferior/posterior STEMI                  | 84.9%         | 15.1%         |         |
| Coronary angiography                      |               |               |         |
| One-vessel disease                        | 88.7%         | 11.3%         | <0.001  |
| Two-vessel disease                        | 83.0%         | 17.0%         |         |
| Three-vessel disease                      | 70.1%         | 29.9%         |         |
| Successful pPCI                           | 84.2%         | 15.8%         | <0.001  |
| Unsuccessful pPCI                         | 49.2%         | 50.8%         |         |
| LVEF >50%                                 | 91.2%         | 8.8%          | <0.001  |
| LVEF 30–49%                               | 77.2%         | 22.8%         |         |
| LVEF <30%                                 | 39.7%         | 60.3%         |         |

CathLab, catheterization laboratory; LVEF, left ventricle ejection fraction; pPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

Table 3  Predictive model for cardiovascular mortality

| Medical history at presentation          | Odds ratio | 95% confidence interval | P-value |
|------------------------------------------|------------|-------------------------|---------|
| Age                                      | 1.0950     | 1.0839–1.1063           | <0.0001 |
| Known diabetes mellitus                  | 1.3915     | 1.0873–1.7808           | 0.0314  |
| Known renal insufficiency                | 2.0586     | 1.1224–3.7757           | 0.0202  |
| Previous heart failure                   | 3.4773     | 1.6171–7.4774           | 0.0025  |
| Clinical characteristics at presentation |            |                         |         |
| Killip class                              | 2.0780     | 1.8760–2.3019           | <0.0001 |
| Successful/unsuccessful pPCI             | 1.0153     | 1.0049–1.0259           | 0.0019  |

pPCI, primary percutaneous coronary intervention.
of cardiovascular morbidity may have an impact on the whole outcome of patients. We suppose that modern treatment for patients with hyperlipidaemia via PCSK9i and SGLT2i for patients with diabetes mellitus or heart failure may lead to a better cardiovascular outcome.

Age as a predictor of death should be assessed separately. Older patients more often have multi-vessel ischaemic heart disease with calcified lesions that may not be appropriate for revascularization. This may lead to a more conservative approach.

Overall, centralized secondary prevention and complex national registries could provide an opportunity and overview for better follow-up of high-risk patients; they might enable more intensive and precise treatment of the underlying risk factors.

Limitations
This was a retrospective, academic study with a large sample from two cardiac centres. Our dataset only included parameters from two independent hospital registries; therefore, it did not include routinely collected data [e.g. the type of stent used (bare-metal or drug-eluting) and whether only balloon angioplasty was conducted]. The long-term outcomes were only evaluated from a mortality perspective; data regarding morbidity and hospitalizations were unavailable.

Conclusion
The mortality associated with myocardial infarction remains high despite intensive secondary preventive care. Cardiovascular diseases remain the leading cause of long-term mortality after pPCI in the Central European population. Our novel predictive model provides risk stratification and could identify high-risk patients who might benefit from a more aggressive approach. Benefits may include...
improvements in quality of life and life expectancy, as well as reduced socioeconomic consequences.

Acknowledgements
The authors thank the Institute of Health Information and Statistics of the Czech Republic for providing mortality data.

Funding
Supported by project Interventional treatment of life-threatening cardiovascular diseases - INTERCARDIS, project EU Nr. CZ.02.1.01/0.0/0.0/16_026/0008388.

Conflict of interest: potential conflict of interest.
P. T. reports consultant contracts, lecture fees, and grant support from Medtronic and BBraun. P. T. reports consultant contracts, lecture fees, and grant support from Medtronic and BBraun. Marek Neuberg is an employee of Medtronic Czechia. All other authors have no potential conflict of interest.

Data availability
The data underlying this article will be shared on reasonable request to the corresponding author.

References
1. Parodi G, Memisha G, Valenti R, Trapani M, Migliorini A, Santoro GM, Antonucci D. Five year outcome after primary coronary intervention for acute ST elevation myocardial infarction: results from a single centre experience. Heart 2005;91:1541-1544.
2. Wang F, Gulati R, Lennon RJ, Lewis BR, Park J, Sandhu GS, Wright RS, Lerman A, Herrmann J. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Mayo Clin Proc 2016;91:1680-1692.
3. Fokkema NL, James sk, Albertsson P, Aasa M, Akerblom A, Calais F, Eriksson P, Jensen J, Schersten F, de Smet BJ, Sjögren I, Tornvall P, Lagerqvist B. Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eurointervention 2016;12:303-311.
4. Pedersen F, Butrymovich V, Kelbaek H, Wachtell T, Heldquist S, Kastrup J, Holmvang L, Clemmensen P, Engstrem T, Grande P, Saunamäki K, Jørgensen E. Short- and long-term outcome of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 2014; 64:2101-2108.
5. Yamashita Y, Shiomi H, Morimoto T, Yaku H, Furukawa Y, Nakagawa Y, Ando K, Kadota K, Abe M, Nagao K, Shizuta S, Ono K, Kimura T; CREDO-Kyoto AMI Registry Investigators. Cardiac and noncardiac causes of long-term mortality in ST-segment-elevation acute myocardial infarction patients who underwent primary percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes 2017;10: e002790.
6. Widimsky P, Bilikova D, Penicka M, Novak M, Lanikova M, Porizka V, Groch L, Zeltzico M, Budensinsky T, Aschermann M; PRAGUE Study Group Investigators. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years’ follow-up of the PRAGUE-2 Trial. Eur Heart J 2007;28: 679-684.
7. Kozieradzka A, Kamiński KA, Maciorkowska D, Olczewska M, Dobrzycki S, Nowak K, Kralisz P, Prokopczuk P, Musial WJ. GRACE, TIMI, Zwoile and CADILLAC risk scores-do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively? Int J Cardiol 2011;148:70-75.
8. Cui K, Lyu S, Song X, Liu H, Yuan F, Xu F, Zhang M, Wang W, Zhang M, Zhang D, Tian J. Long-term safety and efficacy of staged percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction and multivessel coronary disease. Am J Cardiol 2019;124:334-342.
9. Doost Hosseiny A, Moloi S, Chandrasekhar J, Farshid A. Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI. Open Heart 2016;3:e000405.
10. Klancik V, Kocka V. Five-year outcome after STEMI in primary PCI era. Interv Akut Kardiol 2021;20:106-110.
11. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143: 29-36.
12. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. 3rd ed. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2013. p1-500.
13. Ciřková R, Bruthans J, Wohlfahrt P, Krajcovíčková A, Šulc P, Eremlísková L, Pudil J, Linhart A, Widimsky J, Fillipovsky J, Mayer O, Lánská V, Polendré R, Štávěk P. The prevalence of major cardiovascular risk factors in the Czech population in 2015-2018. The Czech post-MONICA study. Cor Vasa 2020;62:6-16. doi: 10.33678/cor.2020.010
14. Bulluck H, Zheng H, Chan WY, Foin N, Foo DC, Lee CW, Lim ST, Sahlen A, Tan HC, Tan JW, Tong KL, Wong AS, Wong PE, Yeo RK, Foo LL, Chua TS, Koh TH, Hausenloy DJ. Independent predictors of cardiac mortality and hospitalization for heart failure in a multi-ethnic Asian ST-segment elevation myocardial infarction population treated by primary percutaneous coronary intervention. Sci Rep 2019;9:10072.
15. Wakabayashi K, Romaguera R, Laynez-Carnicero A, Maluenda G, Ben-Dor I, Sardi GL, Gaglia MA, Mahmoudi M, González MA, Delhaye C, Torguson RL, Xue Z, Suddath WO, Satlier LF, Kent KM, Pichard AD, Lindsay JA, Waksman R. Impact of smoking on acute phase outcomes of myocardial infarction. Coron Artery Dis 2011;22:217-222.
16. Eise A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, Smith SC, Ohman EM, Scirica BM; the REACH Registry Investigators. Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. J Am Heart Assoc 2016;5: e004080.